MedElevator
Войти в исследования International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Detection of hepatitis B virus in cerebrospinal fluid of people with HIV-associated cryptococcal meningitis in Botswana.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Phakedi Basetsana K S, Phinius Bonolo B, Molebatsi Kesaobaka, Kelentse Nametso, Bhebhe Lynnette, Dobo Linda Mpofu, Baruti Kabo, Tsayang Chanana, Mulenga Graceful, Ratsoma Tsholofelo, Mpebe Gorata, Ndlovu Nokuthula S, Choga Wonderful, Lawrence David S, Moyo Sikhulile, Jarvis Joseph N, Gobe Irene, Anderson Motswedi, Gaseitsiwe Simani
Аннотация
OBJECTIVES: To investigate hepatitis B virus presence in plasma and cerebrospinal fluid (CSF) of people living with HIV (PLWH) associated cryptococcal meningitis (CM) in Botswana.
METHODS: Baseline plasma and CSF samples from the AMBIsome Therapy Induction Optimization for CM study, which enrolled adult PLWH with CM in Botswana (2018-2021), were screened for HBV surface antigen (HBsAg), viral load, occult hepatitis B infection (HBsAg- and HBV DNA+), and sequenced the surface/polymerase region to assess mutations and genetic diversity.
RESULTS: Among 81 participants, 67.9% (55/81) were male, median age was 40 years (IQR: 34-44), median CD4+ T cell count was 29 cells/µl (IQR: 11-65). Available plasma (n = 77) and CSF (n = 74) samples were screened for HBV. Plasma HBsAg prevalence was 29.7% (95% CI: 20-42 (19/64) and 18.8% (95% CI: 10-30 (13/69) in CSF. Occult HBV infection (HBsAg- and HBV DNA+) was detected in 35.5% (95% CI: 21-53, 11/31) in plasma and 2.4% (95% CI: 0.06-13, 1/42) in CSF. ART exposure was associated with reduced plasma HBV DNA (P = 0.04), with no significant effect observed in CSF (P = 0.7). In plasma-CSF pairs, plasma showed higher detection rates for HBsAg, HBV DNA, and OBI (P ≤ 0.01). HBV was sequenced in 5 CSF and 4 plasma samples, including 3 pairs. Genotypes A and D detected were concordant between pairs, but 2 pairs showed mutational frequency discordance.
CONCLUSION: HBsAg and HBV DNA were detected in CSF of PLWH with CM, suggesting the CSF may be a reservoir.
METHODS: Baseline plasma and CSF samples from the AMBIsome Therapy Induction Optimization for CM study, which enrolled adult PLWH with CM in Botswana (2018-2021), were screened for HBV surface antigen (HBsAg), viral load, occult hepatitis B infection (HBsAg- and HBV DNA+), and sequenced the surface/polymerase region to assess mutations and genetic diversity.
RESULTS: Among 81 participants, 67.9% (55/81) were male, median age was 40 years (IQR: 34-44), median CD4+ T cell count was 29 cells/µl (IQR: 11-65). Available plasma (n = 77) and CSF (n = 74) samples were screened for HBV. Plasma HBsAg prevalence was 29.7% (95% CI: 20-42 (19/64) and 18.8% (95% CI: 10-30 (13/69) in CSF. Occult HBV infection (HBsAg- and HBV DNA+) was detected in 35.5% (95% CI: 21-53, 11/31) in plasma and 2.4% (95% CI: 0.06-13, 1/42) in CSF. ART exposure was associated with reduced plasma HBV DNA (P = 0.04), with no significant effect observed in CSF (P = 0.7). In plasma-CSF pairs, plasma showed higher detection rates for HBsAg, HBV DNA, and OBI (P ≤ 0.01). HBV was sequenced in 5 CSF and 4 plasma samples, including 3 pairs. Genotypes A and D detected were concordant between pairs, but 2 pairs showed mutational frequency discordance.
CONCLUSION: HBsAg and HBV DNA were detected in CSF of PLWH with CM, suggesting the CSF may be a reservoir.